drugset / Trial / NCT00829829

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

NCT00829829

Phase 3 Completed 241 enrolled Regeneron Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are beginning allopurinol treatment for gout. Subjects will participate in this study for approximately 22 weeks. Rilonacept is being studied for use in preventing allopurinol-induced gout flares.

Timeline

Start
2009-02
Primary completion
2010-05
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rilonacept Protein / enzyme biologic 80 mg Subcutaneous
Comparator Rilonacept Protein / enzyme biologic 160 mg Subcutaneous

Indications